Date de mise à jour : 14/10/14

Dr. Jamal TEMSAMANI

Vice-President R&D Préclinique

AdresseProfessionnelle :

Syntem, Parc Scientifique Georges Besse
30000 Nîmes FRANCE

Email : jtemsamani@syntem.com 

Téléphone : (33) 4 66 04 86 66
Fax : (33) 4 66 04 86 67

Site internet décrivant mes travaux :  http://www.syntem.com 

Formation :  

Dr. Temsamani is Vice-President of Preclinical Research & development at Syntem.  He has served the company as Director of Preclinical R&D since 1998 and as Vice-President since 2001. Prior to joining Syntem, he held several positions with Hybridon Inc in the US from 1990 to 1998, where he has served successively as Associate Director and Director of Discovery. In 1997, he was appointed Scientific Director of Hybridon Europe where he was responsible for supervising European collaborations. Dr. Temsamani received his Ph.D in Molecular Biology and Biochemistry from the University of Montpellier in France and the completed a post-doctoral fellowship at the Worcester Foundation for Biomedical Research. He has published more than 50 scientific articles and he is co-inventor of 30 patents.

Domaine de compétences techniques et scientifiques :

Développement préclinique des molécules thérapeutiques
Expertise dans le domaine du système nerveux central
Vectorisation des molécules thérapeutiques à travers la barrière hémato-encéphalique

Thèmes principaux de recherche 

Vectorisation de médicaments à travers la BHE
Développement de médicaments pour le traitement de la douleur et des cancers du cerveau

5 principales publications décrivant vos travaux :

1.      Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated strategy  C Rousselle et al, (2003). J Pharmacol Exp Ther.  306, 371-376.

2.      Peptide delivery to the brain via adsorptive-mediated endocytosis: Advances with SynB vectors. G Drin et al,  (2002) AAPS PharmSci, 4 (4) article 26.

3.    New Advances in the Transport of Doxorubicin Through the Blood-Brain Barrier by a Peptide-Vector Mediated Strategy. C Rousselle et al.  (2000), Moleculary Pharmacology, Vol 57, 679-686.

4. Induction of antigen specific CTL responses using antigens conjugated to short peptide vectors F Day, Y Zhang, P Clair, K H  Grabstein,  M Mazel, AR Rees, M Kaczorek and J Temsamani. (2003). J. Immunology. 170, 1498-1503.

5. Doxorubicin-peptide conjugates overcome multidrug resistance. M Mazel, P Clair, C Rousselle, P Vidal, JM Scherrmann, D Mathieu & J Temsamani. (2001) Anti-Cancer Drugs Vol 12 107-116

Observations (proposition d’accueil de doctorants, post-doctorants, commentaires libres, etc…) :